Invitrogen™ Linavonkibart Recombinant Monoclonal Antibody

Linavonkibart, also known as SRK-181, is a fully human IgG4 monoclonal antibody designed to selectively inhibit the latent transforming growth factor-beta isoform 1 (TGFB1). Transforming growth factor-B1 (TGF-B1) is a key member of the TGF-beta family, a group of evolutionarily conserved polypeptide growth factors. The gene encoding TGF-B1 is located on chromosome 19 at the 19q13.2 locus. Structurally, TGF-B1 is synthesized as a precursor, which is then cleaved to produce a mature polypeptide that forms a dimeric protein. Functionally, TGF-B1 plays a crucial role in cellular processes such as proliferation, differentiation, and apoptosis, and is essential for regulating immune responses, maintaining tissue homeostasis, and orchestrating wound healing. Dysregulation of TGF-B1 signaling has been implicated in various pathological conditions including cancer, fibrosis, and autoimmune disorders. The activation of latent TGF-B1 stored in the extracellular matrix is mediated by interaction with integrins and other co-factors that induce conformational changes necessary for its biological activity.